{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-21-123200","form_type":"8-K/A","ticker":"TBPH","cik":"0001583107","company_name":"Theravance Biopharma, Inc.","filed_at":"2021-10-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.146761+00:00","generated_at":"2026-06-28T22:58:26.989960+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Theravance Biopharma amends 8-K to disclose consulting agreement with departing EVP & General Counsel","bullets":["Bradford Shafer, EVP & General Counsel, resigned effective Sep 30, 2021; consulting agreement signed same day.","Consulting term runs Sep 30 to Nov 30, 2021; up to 5 hours/week for transition support.","Restricted share units originally vesting Nov 20, 2021 and Feb 20, 2022 will both vest on Nov 20, 2021.","Agreement includes standard confidentiality, non-solicitation (12 months), and invention assignment provisions."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-21-123200","json":"https://secwatch.observer/filing/0001104659-21-123200.json","markdown":"https://secwatch.observer/filing/0001104659-21-123200.md","text":"https://secwatch.observer/filing/0001104659-21-123200.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583107/000110465921123200/0001104659-21-123200-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583107/000110465921123200/tm2129216d1_8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T22:58:26.989960+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a07fa2e93c","claim":"Bradford Shafer resigned as EVP & General Counsel at Theravance Biopharma, Inc..","evidence_excerpt":"the Company and Mr. Shafer entered into a consulting agreement to facilitate the transition of activities following Mr. Shafer’s departure","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1583107/000110465921123200/0001104659-21-123200-index.htm","confidence":0.85,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"EVP & General Counsel"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}